Eli Lilly Zepound - Search News

Eli Lilly posts mixed quarter

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast.

BioPharma Dive · 1d

Eli Lilly’s earnings, shares lifted by obesity drug sales

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for its weight loss medicines in January.

CNBC on MSN · 1d

Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

BioSpace18h

After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Nasdaq15d

Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Eli Lilly posts mixed quarter

Trending now